Shuxuetong for Prevention of recurrence in Acute Cerebrovascular events with Embolism (SPACE) trial: rationale and design

Hong-Qiu Gu, Xue-Wei Xie, Jing Jing, Xia Meng, Wei Lv, Jian-Dong Yu, Xiang-Ping Lv, Hao Li, Yi-Long Wang, Yong-Jun Wang, Hong-Qiu Gu, Xue-Wei Xie, Jing Jing, Xia Meng, Wei Lv, Jian-Dong Yu, Xiang-Ping Lv, Hao Li, Yi-Long Wang, Yong-Jun Wang

Abstract

Backgrounds: Embolic stroke is one of the main mechanisms of ischaemic stroke. Even if treated with recommended antithrombotic agents, stroke recurrence remains high. The Shuxuetong injection, a purified extract of traditional Chinese medicine widely used for thrombus diseases in clinical practice in China, could be a promising agent to prevent stroke recurrence.

Aims: To describe the design of the Shuxuetong injection for prevention of recurrence in acute ischaemic stroke with embolism mechanisms.

Design: The Shuxuetong for Prevention of recurrence in Acute Cerebrovascular events with Embolism (SPACE) trial is a multicentre, randomised, double-blind, placebo-controlled, parallel-group, superiority trial to evaluate the efficacy and safety of Shuxuetong injection in reducing recurrence or silent new ischaemic lesions on patients with acute embolic stroke within 10 days. An estimated 2416 patients with embolic stroke within 72 hours of symptom onset from 80 hospitals will be randomly assigned to one of two groups receiving Shuxuetong injection or placebo injection for 10 days. The primary endpoint is symptomatic or asymptomatic new cerebral infarction within 10 days after randomisation.

Conclusion: The SPACE Trial will provide valuable evidence for the efficacy and safety of Shuxuetong injection for the prevention of stroke recurrence in patients with imaging-defined embolic stroke.

Clinical trial registration: NCT03090113.

Keywords: Lesion; MRI; Stroke.

Conflict of interest statement

Competing interests: The SPACE programme is an investigator-initiated study and mainly funded by the Ministry of Science and Technology of the People’s Republic of China. Mudanjiang Youbo Pharmaceutical Co., Ltd partly funded this programme; however, the company was not involved in the study design, data collection, data cleaning, data analysis, data interpretation and manuscript writing.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of the Shuxuetong for Prevention of recurrence in Acute Cerebrovascular events with Embolism (SPACE) trial.

References

    1. Vos T, Barber RM, Bell B, et al. . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;386:743–800. 10.1016/S0140-6736(15)60692-4
    1. Feigin VL, Krishnamurthi RV, Parmar P, et al. . Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study. Neuroepidemiology 2015;45:161–76. 10.1159/000441085
    1. Yang G, Wang Y, Zeng Y, et al. . Rapid health transition in China, 1990-2010: findings from the global burden of disease study 2010. Lancet 2013;381:1987–2015. 10.1016/S0140-6736(13)61097-1
    1. Zhou M, Wang H, Zhu J, et al. . Cause-Specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the global burden of disease study 2013. Lancet 2016;387:251–72. 10.1016/S0140-6736(15)00551-6
    1. Hart RG, Diener H-C, Coutts SB, et al. . Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429–38. 10.1016/S1474-4422(13)70310-7
    1. Kumar MA, Vangala H, Tong DC, et al. . Mri guides diagnostic approach for ischaemic stroke. J Neurol Neurosurg Psychiatry 2011;82:1201–5. 10.1136/jnnp.2010.237941
    1. Jauch EC, Saver JL, Adams HP, et al. . Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2013;44:870–947. 10.1161/STR.0b013e318284056a
    1. Kernan WN, Ovbiagele B, Black HR, et al. . Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2014;45:2160–236. 10.1161/STR.0000000000000024
    1. Markus HS, Droste DW, Kaps M, et al. . Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111:2233–40. 10.1161/01.CIR.0000163561.90680.1C
    1. Wong KSL, Chen C, Fu J, et al. . Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (clair study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489–97. 10.1016/S1474-4422(10)70060-0
    1. Amarenco P, Davis S, Jones EF, et al. . Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014;45:1248–57. 10.1161/STROKEAHA.113.004251
    1. Go AS, Fang MC, Udaltsova N, et al. . Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (atria) study. Circulation 2009;119:1363–9. 10.1161/CIRCULATIONAHA.108.816082
    1. Zhang X, Xiao B, Hu C-L. [Study in the mechanism of Shuxuetong injection on antithrombosis and thrombolysis]. Zhongguo Zhong Yao Za Zhi 2005;30:1950–2.
    1. Zhang W. Effects of Shuxuetong injection applied in acute ischemic stroke. J Acute Dis 2016;5:507–11. 10.1016/j.joad.2016.08.023
    1. Hong K-S, Lee S-H, Kim EG, et al. . Recurrent ischemic lesions after acute atherothrombotic stroke. Stroke 2016;47:2323–30. 10.1161/STROKEAHA.115.012293
    1. James S, Åkerblom A, Cannon CP, et al. . Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (Plato) trial. Am Heart J 2009;157:599–605. 10.1016/j.ahj.2009.01.003
    1. Gong X, Sucher NJ. Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Phytomedicine 2002;9:478–84. 10.1078/09447110260571760
    1. Li J, Liu Z, Chen R, et al. . The quality of reports of randomized clinical trials on traditional Chinese medicine treatments: a systematic review of articles indexed in the China national knowledge infrastructure database from 2005 to 2012. BMC Complement Altern Med 2014;14:362 10.1186/1472-6882-14-362

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit